AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2504972
Drug: Tegafur (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur (12 mg/kg/day) + MMC (0.2 mg/kg x 2)
Trial: 969779
Drug: Choleretics administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choleretics administered orally in a dosage two to five times more than the recommended one
Trial: 28234235
Drug: Protease inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitor monotherapy (PI‐mono)
Trial: 22791766
Drug: Concurrent PTH(1-84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent PTH(1-84) and ibandronate for 6 months followed by 18 months of ibandronate
Trial: 22791766
Drug: Sequential PTH(1-84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential PTH(1-84) for two courses of 3 months followed by 9 months of ibandronate
Trial: 22791766
Drug: Concurrent PTH(1-84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent PTH(1-84) and ibandronate
Trial: 22791766
Drug: Sequential PTH(1-84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential PTH(1-84)
Trial: 22791766
Drug: Concurrent and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent and sequential therapies
Trial: 19354091
Drug: Functional Restoration
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Restoration (FR) treatment group
Trial: 19354091
Drug: Standard anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard anesthesia pain clinic treatment comparison group
Trial: 9818296
Drug: Acenocoumarol once
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol once daily
Trial: 9818296
Drug: Acenocoumarol twice
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acenocoumarol twice daily
Trial: 1827042
Drug: isosorbide‐5‐mononitrate (ISMN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isosorbide‐5‐mononitrate (ISMN) 20 mg
Trial: 25828636
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Trial: 25828636
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of irbesartan/hydrochlorothiazide FDC tablet (300/12.5 mg)
Trial: 21175274
Drug: Patient-led titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-led titration of insulin glargine
Trial: 21175274
Drug: Physician-led titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-led titration of insulin glargine
Trial: 2604532
Drug: Classical Tetracoq
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical Tetracoq vaccine
Trial: 2604532
Drug: Inactivated poliomyelitis
RxNorm normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliomyelitis vaccines prepared on monkey kidney cells
Trial: 2604532
Drug: Inactivated poliomyelitis
RxNorm normalized name: Inactivated poliomyelitis vaccine (V.C.O.) type 2 MEF1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated poliomyelitis vaccines prepared on Vero-type continuous cell lines
Trial: 2604532
Drug: Polio vaccine
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polio vaccine placed in a 2-compartment syringe separating the polio vaccine from the DPT
Trial: 1234488
Drug: Codeine phosphate
RxNorm normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine phosphate syrup, B.P.C.
Trial: 1234488
Drug: Syrup alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup alone
Trial: 26576178
Drug: Risperidone 6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 6 mg/day plus Zn sulfate (50 mg elemental Zn three times a day)
Trial: 21410733
Drug: AZD1386 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1386 30 mg
Trial: 21410733
Drug: AZD1386 95
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1386 95 mg
Trial: 17217713
Drug: Xuezhikang 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang 0.6 g Bid
Trial: 14633563
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL dilute solution (0.1%/0.5 microg/mL ropivacaine/fentanyl)
Trial: 14633563
Drug: 8 mL
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL concentrated solution
Trial: 14633563
Drug: 12 mL
RxNorm normalized name: syringe, disposable, 12 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mL ropivacaine and 6 microg fentanyl
Trial: 11084114
Drug: Ventricular resynchronization
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventricular resynchronization therapy (VRT) by left or biventricular stimulation
Trial: 9084896
Drug: Fluoxetine and
RxNorm normalized name: fluoxetine and psycholeptics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine and Maprotiline
Trial: 31308644
Drug: Behavioral medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral medicine intervention in physical therapy (BMPI)
Trial: 25415733
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose (CTDIvol, 38.4 mGy)
Trial: 25415733
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose (CTDIvol, 24.6 mGy) with 30% ASIR
Trial: 25415733
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose (CTDIvol, 15.4 mGy) with 50% ASIR
Trial: 25415733
Drug: All ASIR
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All ASIR percentages regardless of radiation dose
Trial: 22805387
Drug: Cefotaxime/heparin lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime/heparin lock
Trial: 18065789
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin lock
Trial: 19124398
Drug: Olmesartan (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (20-40 mg/day)
Trial: 12087569
Drug: Once-weekly epoetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly epoetin beta (n = 84)
Trial: 12087569
Drug: Thrice-weekly epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly epoetin beta (n = 89)
Trial: 9451066
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (1 x 10(6) kallikrein activation units)
Trial: 2527473
Drug: Propranolol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (150 mg/day)
Trial: 3294067
Drug: Pindolol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (15 mg/day)
Trial: 31943297
Drug: PegIFNÎ± treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PegIFNÎ± treatment for 48 weeks plus 24 weeks follow-up
Trial: 31943297
Drug: NUCs treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUCs treatment for 104 weeks
Trial: 28167468
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous nutrition therapy (Group A)
Trial: 28167468
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (Group B)
Trial: 21159785
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (3.0 g eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) at a 5:1 ratio)
Trial: 18224442
Drug: naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg twice daily plus omeprazole 20 mg daily
Trial: 18224442
Drug: naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg twice daily plus placebo
Trial: 1389761
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Atenolol and Nifedipine
Trial: 10676687
Drug: Moxonidine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.1 mg b.i.d. (initial dose), increased weekly to 0.2 mg and 0.3 mg b.i.d. as target doses.
Trial: 10676687
Drug: Moxonidine (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.1, 0.2, or 0.3 mg b.i.d.)
Trial: 8452172
Drug: Oral fleroxacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fleroxacin, 400 mg once a day for 4-21 days
Trial: 8452172
Drug: Oral amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin/clavulanate (AMX/CP), 400 mg/125 mg three times a day for 4-21 days
Trial: 3762014
Drug: L-penbutolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-penbutolol (40 mg)
Trial: 3762014
Drug: D-penbutolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penbutolol (40 mg)
Trial: 31306465
Drug: Telephone administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone administered brief HIV risk reduction intervention
Trial: 28184431
Drug: Nintedanib in
RxNorm normalized name: Product containing nintedanib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib in combination with pemetrexed
Trial: 23904191
Drug: Budesonide/formoterol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol maintenance and reliever therapy (SMART™)
Trial: 23904191
Drug: Free combination
RxNorm normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free combination of inhaled corticosteroid (ICS) + long‐acting β2‐agonist (LABA) and as‐needed short‐acting β2‐agonist (SABA)
Trial: 21508090
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (100 μg/d)
Trial: 21508090
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (4000 μg/wk)
Trial: 21508090
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (4000 μg/d)
Trial: 17332146
Drug: MTHFR genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTHFR genotype (TT vs CC)
Trial: 16282699
Drug: Pamidronate (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (125 mg) + oral calcium (500 mg/day) for 3 months
Trial: 16282699
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (500 mg/day) for 3 months
Trial: 11287080
Drug: Pivagabine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivagabine (900 mg, twice a day)
Trial: 3447933
Drug: RO 13-6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13-6438 (10 mg)
Trial: 3447933
Drug: RO 13-6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13-6438 (20 mg)
Trial: 3447933
Drug: RO 13-6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13-6438 (30 mg)
Trial: 3447933
Drug: RO 13-6438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO 13-6438 (all doses)
Trial: 20825743
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and Metformin Therapy
Trial: 16020407
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein 15 g/d
Trial: 16020407
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein 25 g/d
Trial: 8566673
Drug: Metronidazole 250mg
RxNorm normalized name: METRONIDAZOLE 250MG TAB
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 250mg plus Amoxicillin 500mg T.I.D for 10 days
Trial: 7010651
Drug: Preoperative irradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative irradiation therapy (700 rads X 2)
Trial: 24447296
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine at 1 μg.kg(‐1)
Trial: 24447296
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine at 1.5 μg.kg(‐1)
Trial: 24447296
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine at 2 μg.kg(‐1)
Trial: 22915643
Drug: Hydroxyurea (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (20 mg/kg/d)
Trial: 21067805
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg simvastatin daily
Trial: 21067805
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg simvastatin daily
Trial: 17922743
Drug: Hemoscan and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoscan and Crit‐Line combination
Trial: 17922743
Drug: BVM and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BVM and Crit‐Line combination
Trial: 10068580
Drug: High-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose subcutaneous interleukin-2 (7.5 million IU twice a day)
Trial: 10068580
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous interleukin-2 (1.5 million IU twice a day)
Trial: 7478680
Drug: Morphine solution
RxNorm normalized name: morphine Injectable Solution
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine solution taken at 4-hourly intervals for 7 days under direct nursing supervision
Trial: 7478680
Drug: Morphine solution
RxNorm normalized name: morphine Injectable Solution
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine solution
Trial: 7443365
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment control
Trial: 17209188
Drug: Iron supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplement (100 mg Fe/d as ferrous gluconate)
Trial: 15182139
Drug: Medication taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication taking behavior
Trial: 8739025
Drug: Tepoxalin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin (35 to 300 mg)
Trial: 1764497
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with nitrendipine (10-40 mg/day), enalapril (5-20 mg/day), and hydrochlorothiazide (12.5-25 mg/day) as necessary.
Trial: 20064822
Drug: RAAS inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAAS inhibitors
Trial: 27753650
Drug: Pregabalin CR
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin CR (82.5 to 660 mg/d)
Trial: 25541333
Drug: adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab 40 mg every other week for 24 weeks, then open-label adalimumab for up to 5 years
Trial: 19532100
Drug: Indapamide and
RxNorm normalized name: Indapamide and perindopril only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide and ACE-inhibitor (if needed)
Trial: 19532100
Drug: ACE-inhibitor and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-inhibitor and angiotensin receptor blocker therapy
Trial: 19532100
Drug: Thiazide diuretics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretics, ACE-inhibitors, or angiotensin receptor blockers (if ACE-inhibitor intolerant)
Trial: 17431603
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg tadalafil
Trial: 11354304
Drug: Prosorba treatment
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prosorba treatment
Trial: 7746027
Drug: Limptar tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limptar tablets (1 tablet containing 215.5 mg quinine and 167.2 mg theophylline)
Trial: 7746027
Drug: Limptar N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limptar N tablets (1 tablet containing 165.75 mg quinine)
Trial: 7746027
Drug: Chininum dihydrochloricum
RxNorm normalized name: Ancylostoma caninum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chininum dihydrochloricum Buchler solution for injection (infusion of 163.3 mg quinine)
Trial: 7746027
Drug: Euphyllin 0.48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euphyllin 0.48 (short infusion of 168.6 mg theophylline)
Trial: 28957960
Drug: Latanoprost/dorzolamide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost/dorzolamide combination
Trial: 28957960
Drug: Dorzolamide monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide monotherapy
Trial: 20860592
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with low-level laser therapy
Trial: 20860592
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment alone (Control)
Trial: 9351762
Drug: Control pamphlet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control pamphlet on daily activities during pregnancy
Trial: 8458315
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy supplement (3.31 MJ daily) for 3 months
Trial: 8458315
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy supplement
Trial: 26572887
Drug: CT scanogram
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT scanogram with 10% of the standard dose of ionizing radiation
Trial: 26572887
Drug: CT scanogram
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT scanogram with 90% of the standard dose of ionizing radiation
Trial: 26572887
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of native and repaired femurs using both doses
Trial: 16270700
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish (Duraphat) treatment applied twice a year at six-month intervals in school settings among 854 adolescents.
Trial: 2878490
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump (CSII)
Trial: 27126957
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group consumed fermented milk with Bifidobacterium lactis HN019 (80 mL daily, 2.72 × 10^10 CFU) for 45 days
Trial: 22520791
Drug: Self-monitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-monitoring of blood pressure and self-titration of antihypertensive medication
Trial: 11926889
Drug: Pramipexole, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole, 0.5 mg 3 times per day with levodopa placebo (n = 42)
Trial: 11926889
Drug: Carbidopa/levodopa, 25/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n = 40)
Trial: 7753739
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and heparin (adjunctive drugs)
Trial: 7753739
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers and angiotensin-converting enzyme inhibitors
Trial: 8018458
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg four times daily
Trial: 7415650
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units of subcutaneous heparin twice a day for a fortnight
Trial: 29615077
Drug: SGI-110 (guadecitabine)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGI-110 (guadecitabine) combined with gemcitabine and cisplatin (GC) chemotherapy